First-Line Therapy for Metastatic Non–Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches
Presented by Joshua Bauml, MD, and Christina Knepley, CRNP
From Penn Medicine, Philadelphia
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):260–265 |
© 2020 Harborside™
At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding clinical data supporting the use of targeted and immune checkpoint inhibitor therapies, and managing adverse events.
For access to the full length article, please sign in